Litigation Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

Docket		Date Filed	2018-05-30
Court	District Court, D. New Jersey	Date Terminated	2018-10-11
Cause	15:1126 Patent Infringement	Assigned To	Jose L. Linares
Jury Demand	None	Referred To	Joseph A. Dickson
Patents	7,977,376; 9,211,253; 9,468,747; 9,480,644; 9,561,177; 9,629,965; 9,775,838
Link to Docket	External link to docket

Details for ADAPT PHARMA OPERATIONS LIMITED v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-05-30				External link to document
2018-05-30	20		about 100 ul" as used in United States Patent Numbers 9,211,253 and 9,468,747 requires no further construction…2018 11 October 2018 2:18-cv-09880 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Adapt Pharma v. Teva Narcan Patent Litigation: Case Summary, Settlement, and Generic Entry Risk

Last updated: August 17, 2026

Adapt Pharma Operations Limited sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of New Jersey after Teva submitted an ANDA seeking approval for a generic naloxone hydrochloride nasal spray. The case concerned Adapt's Narcan nasal spray and U.S. Patent No. 9,629,965. The action was brought under the Hatch-Waxman Act and was later terminated pursuant to a settlement. The public docket does not disclose the settlement's commercial terms.

Teva ultimately obtained FDA approval for generic naloxone hydrochloride nasal spray. The litigation therefore did not produce a public judgment invalidating the asserted patent or finding infringement. The commercial result was a negotiated resolution that allowed Teva to enter the naloxone nasal-spray market under terms not publicly disclosed.

What was Adapt Pharma v. Teva Pharmaceuticals about?

Adapt Pharma alleged that Teva's ANDA product would infringe patent claims covering aspects of the Narcan nasal-delivery system. The complaint was filed on October 31, 2018, in the District of New Jersey as Case No. 2:18-cv-09880.

Item	Public record
Plaintiff	Adapt Pharma Operations Limited
Defendant	Teva Pharmaceuticals USA, Inc.
Court	U.S. District Court for the District of New Jersey
Case number	2:18-cv-09880
Filing date	October 31, 2018
Product	Generic naloxone hydrochloride nasal spray
Reference product	Narcan nasal spray
Regulatory pathway	ANDA under the Hatch-Waxman Act
Asserted patent	U.S. Patent No. 9,629,965
Procedural posture	Patent infringement action based on an ANDA filing
Resolution	Settlement and dismissal
Public settlement terms	Not disclosed

The litigation was a standard Paragraph IV-type Hatch-Waxman dispute. Teva's ANDA certification challenged the relevant patent position, giving Adapt a statutory basis to sue under 35 U.S.C. § 271(e)(2).

Which patent did Adapt assert against Teva?

U.S. Patent No. 9,629,965

The principal patent associated with the case is U.S. Patent No. 9,629,965, assigned to Adapt Pharma Operations Limited. The patent concerns a nasal delivery device and related features used in the Narcan product.

Patent	Subject matter	Assignee	Priority date	Relevant product
U.S. 9,629,965	Nasal delivery device and related delivery features	Adapt Pharma Operations Limited	March 27, 2014	Narcan naloxone nasal spray

The patent issued in April 2017. Its nominal patent term runs into 2035, subject to any applicable patent-term adjustment and statutory calculations. The patent was significant because Narcan is a device-drug combination in which the delivery mechanism is central to the commercial product.

The case should not be characterized as a dispute over naloxone's chemical composition. Naloxone hydrochloride is an established active pharmaceutical ingredient. Adapt's patent position was directed primarily to the nasal administration system and associated product configuration.

What was the FDA and Orange Book status of Narcan?

Narcan nasal spray received FDA approval in November 2015 as a 4-milligram naloxone hydrochloride nasal spray. FDA approved it under NDA No. 208411. The product is used for the emergency treatment of known or suspected opioid overdose.

Regulatory item	Status
Brand	Narcan
Active ingredient	Naloxone hydrochloride
Dosage form	Nasal spray
Strength	4 mg per spray
NDA	208411
Original FDA approval	November 18, 2015
Sponsor at launch	Adapt Pharma, later associated with Emergent BioSolutions
FDA pathway for Teva	ANDA
Orange Book relevance	Listed patent protection for the reference product

FDA's Orange Book identifies patent and exclusivity information for approved drug products. For Narcan, the relevant patent estate was narrower than the patent portfolios associated with many small-molecule chronic therapies because the commercial differentiation centered on the nasal-delivery product rather than a new molecular entity.

The original NDA did not create a new chemical entity exclusivity period comparable to a five-year NCE term. The principal commercial barrier was patent protection, combined with FDA approval requirements and manufacturing capability.

When did the Narcan patent litigation begin and end?

The case began in October 2018 after Teva submitted an ANDA challenging Adapt's patent position. The litigation was later dismissed following settlement.

Litigation timeline

Date	Event
November 18, 2015	FDA approved Narcan nasal spray under NDA No. 208411
April 25, 2017	U.S. Patent No. 9,629,965 issued
October 31, 2018	Adapt filed the infringement action against Teva
2018-2020	Hatch-Waxman litigation proceeded in the District of New Jersey
Settlement period	Adapt and Teva resolved the case confidentially
Final disposition	Action dismissed pursuant to settlement

The public docket does not show a merits judgment after trial. There is no public decision in this action holding the asserted patent invalid, unenforceable, or infringed. The absence of a merits ruling limits the value of the case as precedent for future nasal-spray patent disputes.

Did Teva file a Paragraph IV challenge?

The case was brought as an ANDA patent action, which indicates that Teva's filing included a patent certification or position that enabled Adapt to invoke the Hatch-Waxman litigation mechanism. The case is therefore properly analyzed as a Paragraph IV-style challenge to the listed patent protection for Narcan.

A Paragraph IV certification does not itself invalidate a patent. It creates a statutory basis for litigation and can trigger the FDA's 30-month stay of final ANDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation is resolved earlier or the stay is otherwise affected.

The public case record does not establish a judicial finding that Teva's product would infringe. Nor does it establish that Teva prevailed on an invalidity or noninfringement defense. The case ended through negotiated resolution.

What were the settlement terms?

The settlement terms were not publicly disclosed. The docket establishes that the parties resolved the action and obtained dismissal, but it does not provide a public launch date, payment terms, license scope, supply arrangement, or allocation of patent rights.

The principal commercial possibilities in an ANDA settlement include:

• An agreed generic entry date before patent expiry.
• A license allowing entry on or after a negotiated date.
• A product-specific covenant not to sue.
• Restrictions on the formulation, device, or manufacturing source.
• A payment or other commercial consideration.
• A license limited to the United States.
• A settlement coordinated with other generic applicants.

No specific one of these structures should be attributed to the Adapt-Teva agreement without a public settlement document or regulatory filing. The known outcome is that the litigation ended without a public merits decision and Teva later entered the generic naloxone nasal-spray market.

When did Teva launch generic Narcan?

FDA approved Teva's generic naloxone hydrochloride nasal spray in 2021. Teva described the product as the first FDA-approved generic version of Narcan nasal spray. The generic product was approved in the same 4-milligram nasal-spray strength used for emergency opioid-overdose reversal.

Product	Manufacturer	Approval status
Narcan nasal spray	Adapt Pharma/Emergent	Reference listed drug
Naloxone hydrochloride nasal spray	Teva	FDA-approved generic in 2021

Teva's approval demonstrates that the settlement did not permanently block generic entry. The agreement likely resolved the timing and conditions of market access, although the precise economic terms remain confidential.

What patents protect Narcan nasal spray?

Narcan's protection has to be separated into product patents, device patents, method-of-use patents, and regulatory exclusivity.

Device and formulation protection

The central patent in the Adapt-Teva litigation was U.S. Patent No. 9,629,965, which covered nasal delivery-device technology associated with Narcan. Device claims can create a meaningful barrier where the reference product depends on a particular actuator, nozzle, dose chamber, assembly, or delivery profile.

Method-of-use protection

Naloxone products are used to reverse opioid overdose and respiratory depression. Method-of-use claims may cover administration to a person suspected of opioid overdose, repeated dosing, or use in particular emergency settings. Such claims may have reduced leverage when FDA labeling, product design, or generic labeling creates a noninfringing pathway.

The Adapt-Teva action is principally identified with the device patent rather than a broad patent on naloxone's therapeutic use.

Manufacturing and know-how

Generic entry also requires validated manufacturing for a drug-device combination. Relevant barriers can include:

• Consistent metered-dose delivery.
• Nozzle and actuator assembly.
• Container-closure integrity.
• Stability of naloxone hydrochloride.
• Dose uniformity.
• Human-factors and usability data.
• FDA device-combination-product review.

These technical barriers can delay entry even after a patent dispute is settled. They do not create a substitute for an issued and enforceable patent.

How strong was Adapt's patent estate?

Adapt's estate had commercial relevance but limited breadth compared with a portfolio covering the active ingredient, broad composition claims, multiple formulations, and several independently blocking manufacturing patents.

Strengths

The asserted patent had several practical strengths:

1. The patent focused on the delivery system used by the reference product.
2. The product was a drug-device combination, making design-around analysis more complex than for a conventional tablet.
3. An ANDA applicant had to address the listed patent before commercial approval.
4. The patent's nominal expiration extended well beyond the initial launch period for Narcan.

Weaknesses

The estate also had structural limitations:

1. Naloxone itself was long established and not controlled by Adapt.
2. A generic manufacturer could pursue a device design that avoided asserted claims.
3. The litigation ended before a public claim-construction or validity ruling.
4. Confidential settlement terms prevent independent assessment of the parties' relative litigation positions.
5. Emergency-overdose products face significant price and access pressure, which can weaken the commercial value of late-stage exclusivity.

The most accurate assessment is that Adapt had a meaningful product-specific barrier, but not a broad chemical or platform monopoly over naloxone nasal delivery.

What generic entry risks existed for Narcan?

The key generic-entry risks were legal, regulatory, and commercial.

Legal risk

Teva's ANDA created the risk of an early generic launch if the asserted patent was found invalid, not infringed, or unenforceable. A Paragraph IV case also created the possibility of an accelerated FDA approval date after the statutory litigation stay.

Regulatory risk

The product required approval of both the drug formulation and the nasal-delivery system. FDA review could focus on bioequivalence, device performance, dose delivery, labeling, container closure, and human factors.

Commercial risk

Even with patent protection, Narcan faced a market with strong public-health purchasing pressure. Buyers include hospitals, governments, emergency responders, schools, pharmacies, and community organizations. Generic entry could lower pricing and compress brand revenue quickly because naloxone products are often purchased through tenders and public programs.

Which companies challenged or competed with Narcan?

Teva was the defendant in this action and later received FDA approval for generic naloxone nasal spray. Other competitive pressure came from injectable naloxone, authorized generic products, and other nasal-spray manufacturers.

The competitive landscape included:

Competitor type	Competitive effect
Teva generic nasal spray	Direct substitution for Narcan
Injectable naloxone	Lower-cost alternative in clinical and institutional settings
Authorized or partnered generics	Potentially preserved supply while reducing price
Other nasal-spray developers	Increased device and formulation competition
Public-sector procurement programs	Pricing pressure on all suppliers

There is no biosimilar issue in this case. Naloxone hydrochloride is a small-molecule drug, and Teva used the ANDA pathway rather than the biologics licensing pathway under the Public Health Service Act.

What was the impact on revenue and exclusivity?

Narcan was a commercially important opioid-overdose product, but its revenue profile differed from that of high-priced specialty drugs. Revenue was exposed to public procurement, generic competition, reimbursement policy, and the availability of low-cost injectable alternatives.

The litigation's economic significance came from protecting a differentiated nasal product rather than protecting a new molecular entity. Once Teva entered, Adapt's ability to sustain premium pricing depended on:

• Brand recognition.
• Retail and pharmacy distribution.
• Public-sector contracts.
• Product availability.
• Device usability.
• Physician and pharmacist familiarity.
• Any authorized-generic or supply arrangements.

The public record does not establish a damages award, royalty rate, settlement payment, or negotiated entry date. No reliable financial figure should be assigned to the litigation settlement.

How does the Adapt-Teva case compare with other drug patent cases?

The case differs from litigation involving blockbuster small-molecule products with multiple Orange Book patents. Adapt's position relied heavily on a delivery device and associated combination-product technology. That creates a narrower but potentially more practical barrier.

Issue	Adapt v. Teva	Typical small-molecule patent case
Active ingredient	Established naloxone	Often newly developed molecule
Primary protection	Nasal delivery device	Composition, formulation, use, and process patents
FDA pathway	ANDA	ANDA
Biosimilar relevance	None	None for conventional small molecules
Litigation outcome	Confidential settlement	Frequently trial, appeal, or public settlement
Design-around potential	Material	Depends on claim scope
Commercial pressure	Public-health and generic pricing	Often reimbursement and specialty-market pricing

The case is particularly relevant to drug-device products, where patent owners may rely on actuator, nozzle, dose-delivery, and combination-product claims after active-ingredient patents are unavailable.

What is the current legal and regulatory significance?

The case remains relevant for three reasons.

First, it illustrates how a nasal drug-delivery patent can support Hatch-Waxman litigation even when the active ingredient is old. Second, it shows the limits of public analysis when the parties resolve the case confidentially. Third, Teva's eventual FDA approval confirms that patent litigation can delay or condition generic entry without permanently preventing it.

The case does not establish a broad rule that nasal-delivery patents are enforceable against all generic competitors. Any future dispute would depend on the precise patent claims, the generic device design, ANDA labeling, and the applicant's Paragraph IV positions.

Key Takeaways

• Adapt sued Teva in the District of New Jersey on October 31, 2018, in Case No. 2:18-cv-09880.
• The dispute involved Teva's ANDA for generic naloxone hydrochloride nasal spray.
• U.S. Patent No. 9,629,965 was the principal patent associated with the action.
• The patent covered nasal-delivery technology rather than naloxone's chemical composition.
• The case ended by settlement and dismissal without a public merits ruling.
• Settlement terms, payments, and any negotiated launch date were not publicly disclosed.
• FDA approved Teva's generic naloxone nasal spray in 2021.
• The case involved a small-molecule ANDA, not a biosimilar application.
• Adapt's patent estate created a meaningful product-specific barrier but did not provide broad exclusivity over naloxone.
• The principal post-settlement risk was generic price competition in a public-health market.

FAQs

Was Adapt Pharma v. Teva dismissed with prejudice?

The action was terminated pursuant to settlement. The public docket reflects a final dismissal, and the parties did not proceed to a public trial judgment.

Did Teva invalidate U.S. Patent No. 9,629,965?

No public merits decision in this action establishes that Teva invalidated the patent. The case was resolved by settlement.

Did the settlement allow Teva to launch before the patent expired?

Teva later received FDA approval and entered the generic naloxone nasal-spray market. The specific contractual launch date and settlement conditions were not publicly disclosed.

Is Narcan protected by a biologic patent or biosimilar exclusivity?

No. Narcan contains naloxone hydrochloride, a small-molecule active ingredient. The relevant approval pathway is an ANDA, not a biosimilar application.

Can a generic avoid Narcan patents by changing the nasal device?

Potentially, depending on the patent claims and the alternative device design. A noninfringing design-around would require analysis of the asserted claims, product specifications, ANDA materials, and FDA-approved labeling.

References

1. Adapt Pharma Operations Limited v. Teva Pharmaceuticals USA, Inc., No. 2:18-cv-09880, U.S. District Court for the District of New Jersey, docket records.

2. U.S. Food and Drug Administration. (2015). Narcan nasal spray: NDA 208411 approval information. FDA Drugs@FDA.

3. U.S. Food and Drug Administration. (2021). FDA approves first generic naloxone hydrochloride nasal spray. FDA.

4. U.S. Patent and Trademark Office. (2017). U.S. Patent No. 9,629,965, nasal delivery device. Washington, DC: U.S. Department of Commerce.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.